Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 15, 2012

Study Completion Date

November 30, 2012

Conditions
MyelomaTransplant-eligible Patients
Interventions
BIOLOGICAL

Ex-vivo expanded effector cells

This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.

Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT00439465 - Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma | Biotech Hunter | Biotech Hunter